Pharming Group N.V. develops and commercializes therapies for rare diseases, focusing on the production of therapeutic proteins through transgenic biotechnology. The company has two approved therapies, RUCONEST® and Joenja®, which target specific rare conditions. Pharming operates internationally, with a commitment to advancing care for rare disease communities and expanding access to its treatments. Its pipeline includes investigational therapies, such as leniolisib and napazimone, aimed at addressing unmet medical needs in underserved populations.